Research Papers:

Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells

Monica Argenziano _, Chiara Lombardi, Benedetta Ferrara, Francesco Trotta, Fabrizio Caldera, Marco Blangetti, Hinanit Koltai, Yoram Kapulnik, Ronit Yarden, Luca Gigliotti, Umberto Dianzani, Chiara Dianzani, Cristina Prandi and Roberta Cavalli

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:35813-35829. https://doi.org/10.18632/oncotarget.26287

Metrics: PDF 1207 views  |   HTML 1801 views  |   ?  


Monica Argenziano1, Chiara Lombardi2, Benedetta Ferrara1, Francesco Trotta2, Fabrizio Caldera2, Marco Blangetti2, Hinanit Koltai3, Yoram Kapulnik3, Ronit Yarden4, Luca Gigliotti5, Umberto Dianzani5, Chiara Dianzani1, Cristina Prandi2 and Roberta Cavalli1

1Department of Drug Science and Technology, University of Turin, Turin, Italy

2Department of Chemistry, University of Turin, Turin, Italy

3Agricultural Research Organization, Volcani Center, Rishon LeTsiyon, Israel

4Georgetown University Medical Center, Washington DC, USA

5Department of Health Sciences, Universita del Piemonte Orientale, Novara, Italy

Correspondence to:

Roberta Cavalli, email: [email protected]

Keywords: strigolactones; GSH/pH-responsive nanosponges; prostate cancer cells; controlled release; intracellular delivery

Received: December 28, 2017     Accepted: October 24, 2018     Published: November 09, 2018


Strigolactones (SLs) are carotenoid-derived plant hormones that exhibit anti-cancer activities. We previously demonstrated that two SL analogues, MEB55 and ST362, inhibit the growth and survival of various cancer cell lines. However, these compounds have low aqueous solubility and stability at physiological pH. Here, we generated SL-loaded glutathione/pH-responsive nanosponges (GSH/pH-NS) to selectively deliver SLs to prostate cancer cells and enhance their therapeutic efficacy. The SLs were readily incorporated into the GSH/pH-NS. The drug loading efficiency was 13.9% for MEB55 and 15.4% for ST362, and the encapsulation efficiency was 88.7% and 96.5%, respectively. Kinetic analysis revealed that release of MEB55 and ST362 from the GSH/pH-NS was accelerated at acidic pH and in the presence of a high GSH concentration. Evaluation of the effects of MEB55- and ST362-loaded GSH/pH-NS on the growth of DU145 (high GSH) and PC-3 (low GSH) prostate cancer cells revealed that the GSH/pH-NS inhibited the proliferation of DU145 cells to a greater extent than free MEB55 or ST362 over a range of concentrations. These findings indicate GSH/pH-NS are efficient tools for controlled delivery of SLs to prostate cancer cells and may enhance the therapeutic efficacy of these compounds.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26287